What Are BRAF Inhibitors and How Do They Work?

BRAF inhibitors are a class of targeted cancer drugs that block a specific mutated protein called BRAF, which acts as a stuck accelerator pedal driving tumor growth. The first of these drugs, vemurafenib, received FDA approval in 2011 after showing rapid tumor shrinkage in patients with advanced melanoma carrying the BRAF V600E mutation.¹ Since then, these drugs have expanded beyond melanoma into lung cancer, thyroid cancer, colorectal cancer, and even pediatric brain tumors. Understanding how they work, who benefits from them, and why they eventually run into limits gives a useful picture of modern precision oncology.

The Normal Job of BRAF and What Goes Wrong

BRAF is a protein that sits along a signaling chain inside cells. When a cell receives a growth signal from outside, that signal passes through a relay of proteins, and BRAF is one of the key handoff points. It activates a protein called MEK, which in turn activates another protein called ERK, and that ultimately tells the cell to grow and divide. In healthy cells, this chain fires only when appropriate signals arrive. Studies of the normal BRAF-MEK complex show that BRAF and MEK sit together in the cell’s cytoplasm in a quiet, inactive state until an upstream signal switches them on.²

When the BRAF gene mutates, the protein it produces gets locked into an “always on” position. The most common mutation by far is called V600E, a single amino acid swap that keeps the BRAF kinase domain firing without any outside signal. This sustained activation promotes cell proliferation, survival, and the formation of new blood vessels feeding the tumor.³ The V600E mutation has been found in roughly half of all melanomas and shows up in colorectal cancer, thyroid cancer, multiple myeloma, and other malignancies.⁴

Not All BRAF Mutations Are the Same

BRAF mutations fall into three classes, and this matters because the drugs that work against one class may not work against the others. Class 1 mutations, including V600E, produce a protein that acts as a single active unit (a monomer) independent of the upstream protein RAS. These are the mutations that current BRAF inhibitors target well. Class 2 mutations produce proteins that pair up into active dimers, again independently of RAS. Class 3 mutations are actually weaker versions of BRAF that still depend on RAS to function.⁵ Current approved BRAF inhibitors were designed to block the monomeric Class 1 form. Against dimerized forms, they are far less effective, which is why newer drugs are being developed to address Classes 2 and 3.

How BRAF Inhibitors Block the Mutant Protein

The mechanism is fairly straightforward in concept. BRAF inhibitors are small molecules that fit into the ATP-binding pocket of the mutant BRAF protein. ATP is the energy molecule that BRAF normally uses to carry out its signaling work, so by occupying that pocket, the drug prevents the protein from passing along its growth signal. Vemurafenib, the first approved BRAF inhibitor, is a competitive inhibitor of this type, meaning it physically competes with ATP for the same binding site on mutant BRAF.⁶

Because these drugs were designed to be selective for the V600E mutant form, they bind much more tightly to the mutant than to normal BRAF. That selectivity is what allows them to hammer tumor cells while leaving most healthy cells relatively unscathed. Three BRAF inhibitors are currently approved for clinical use: vemurafenib, dabrafenib, and encorafenib. All three work on the same principle but differ in their pharmacological profiles, how they’re metabolized, and which side effects they tend to cause.

The Paradoxical Activation Problem

One of the strangest discoveries about first-generation BRAF inhibitors is that in cells with normal BRAF, the drugs can actually speed up the signaling pathway they were designed to shut down. When the drug binds to one partner in a BRAF dimer in cells with normal BRAF or active RAS, it can change the shape of the dimer in a way that activates the other partner. The result is an increase in downstream signaling rather than a decrease. This “paradoxical activation” is not just a lab curiosity. It explains why some patients on BRAF inhibitors develop new skin growths, including squamous cell carcinomas, during treatment. The drug suppresses signaling in melanoma cells carrying V600E but inadvertently boosts it in skin cells with normal BRAF that have other pre-existing mutations pushing them toward abnormal growth.

The phenomenon extends beyond skin side effects. In pediatric brain tumors, for instance, certain BRAF gene fusions produce proteins that naturally function as dimers. Research on one such fusion, called KIAA1549-BRAF, found that the fusion protein forms homodimers resistant to first-generation BRAF inhibitors and is associated with paradoxical activation of the growth pathway.⁷ This finding underscores why mutation type matters so much when choosing treatment.

Why BRAF Inhibitors Are Almost Always Paired with MEK Inhibitors

Early on, clinicians noticed that BRAF inhibitors alone produced dramatic initial responses but that tumors found workarounds quickly. Adding a MEK inhibitor, the protein directly downstream of BRAF in the signaling chain, blocks the pathway at a second point and makes it harder for cancer cells to reroute the signal. In a landmark trial, patients receiving the combination of dabrafenib plus trametinib had a response rate of about 67%, compared with 51% for dabrafenib alone, and their disease took longer to progress.⁸ At six months, 93% of patients on the combination were still alive, versus 85% on the single drug.

A meta-analysis pooling data from multiple trials confirmed that the combination approach consistently outperformed BRAF inhibitors alone on response rate, time to progression, and overall survival.⁹ These results were reinforced by the COLUMBUS trial, which showed that the combination of encorafenib plus binimetinib extended median progression-free survival to about 13 months, compared with roughly 9 months for encorafenib alone, and produced an overall response rate of 68% versus 51%.¹⁰ The combination also had fewer severe side effects than the higher-dose single agent, partly because blocking MEK counters the paradoxical pathway activation that causes skin toxicity. Today, the standard of care for BRAF V600-mutant melanoma is a BRAF/MEK inhibitor pair, not a BRAF inhibitor alone.

What Outcomes Look Like in Practice

Clinical trial results and real-world data tell somewhat different stories, and both are worth knowing. In the original vemurafenib trials, patients with advanced BRAF V600-mutant melanoma had a confirmed response rate of about 53%, a median progression-free survival near 7 months, and a median overall survival close to 16 months.¹¹ For context, before targeted therapy, advanced melanoma patients treated with traditional chemotherapy had median survival measured in single-digit months.

With the newer BRAF/MEK combinations, outcomes have improved further, though the gains are incremental rather than transformative for most patients. Real-world data on 435 patients treated with BRAF/MEK inhibitors found a median overall survival of about 12 months, with roughly 28% of patients alive at two years and 19% at four years.¹² That four-year figure is important: it suggests a meaningful minority of patients get durable benefit. When patients receive BRAF/MEK inhibitors after prior immunotherapy, median progression-free survival is around 8 months and median overall survival about 20 months, with roughly 42% alive at two years.¹³ These numbers are lower than what clinical trials typically report, which makes sense: trials select for healthier patients and more tightly controlled settings.

How Tumors Develop Resistance

The central frustration with BRAF inhibitors is that most tumors eventually figure out how to grow despite the drug. About 20% of melanoma patients don’t respond at all due to built-in resistance, and the majority of those who do respond eventually see their tumors progress.¹⁴ The mechanisms are varied and sometimes stack on top of each other:

Pathway reactivation: The tumor finds ways to turn the same MAPK signaling chain back on. It might amplify the mutant BRAF gene itself, develop splice variants that form drug-resistant dimers, or pick up new mutations in MEK that bypass the block.
Receptor overexpression: Tumor cells can crank up surface receptors like EGFR, PDGFR, or MET, which activate parallel signaling routes that feed into the same growth programs.
RAS mutations: New mutations in RAS proteins upstream of BRAF can increase BRAF dimerization, restarting the pathway even with the drug present.
Microenvironment changes: Interactions between the tumor and surrounding immune and stromal cells can shift to support continued growth.

Recovery of MAPK signaling is the single most common resistance mechanism.¹⁵ This is why researchers keep circling back to the same signaling chain with new drugs and new combinations: the tumor’s default escape route runs through familiar territory.

Side Effects Worth Knowing About

BRAF inhibitors have a distinctive side-effect profile, and the skin bears the brunt. Cutaneous reactions are the most common adverse events reported with these drugs.¹⁶ In one detailed study of patients on vemurafenib, skin side effects included squamous cell carcinomas, warty growths, rashes resembling Darier disease, thickened palms and soles, and changes in existing moles. These effects appeared as early as one week into treatment, with an average onset of about 13 weeks.¹⁷ Photosensitivity, where patients sunburn far more easily than normal, is another well-known issue, particularly with vemurafenib.¹⁸

The squamous cell carcinomas that develop during BRAF inhibitor therapy are generally low-risk and treatable with simple excision. They arise because of the paradoxical activation effect mentioned earlier: in skin cells that already carry certain precancerous mutations, the drug can accelerate growth. Adding a MEK inhibitor dramatically reduces this risk, which is another reason the combination became standard.

Beyond the skin, fever is a common issue with dabrafenib-based regimens. A retrospective study found that about 39% of patients on dabrafenib plus trametinib developed fever syndrome, with most cases appearing in the first month. Patients who developed fever were more likely to discontinue treatment due to the side effect.¹⁹ Cardiovascular effects also deserve attention: nearly half of patients in one analysis experienced at least one cardiac symptom during BRAF/MEK inhibitor therapy, including shortness of breath, changes in heart function, high blood pressure, or abnormal heart rhythms.²⁰

You Need a Test Before You Can Get the Drug

BRAF inhibitors only work on tumors carrying the right mutation, so testing is mandatory before treatment. The standard approach uses a tissue biopsy, where a thin slice of tumor tissue is analyzed for the presence of BRAF V600 mutations. Multiple testing methods exist, from FDA-approved companion diagnostic assays to laboratory-developed tests using DNA or protein-based techniques.²¹ The cobas BRAF test, for instance, is an FDA-approved companion diagnostic that can detect clinically relevant mutations from a single thin tissue section, with high sensitivity and a low detection threshold.²²

This testing requirement means that a patient’s path to BRAF inhibitor therapy starts with accurate molecular profiling. For melanoma, guidelines now recommend testing all patients with unresectable or metastatic disease. For lung cancer, BRAF V600E testing has become a mandatory part of the genomic workup for advanced non-squamous disease.²³ The turnaround time for testing can range from a few days to a couple of weeks depending on the laboratory, which occasionally creates tension when patients need to start treatment quickly.

Beyond Melanoma

While melanoma was the proving ground for BRAF inhibitors, these drugs now have approved or actively investigated uses in several other cancers. In non-small cell lung cancer, the dabrafenib-trametinib combination has shown efficacy in patients with V600E mutations, making it a standard treatment option for that subset. Colorectal cancer has proven more challenging. Even though BRAF V600E mutations occur in colorectal tumors, blocking BRAF alone triggers feedback activation of other growth receptors, particularly EGFR, which sustains tumor signaling. This is why colorectal cancer often requires a triple-drug approach combining a BRAF inhibitor, a MEK inhibitor, and an anti-EGFR antibody. Even with that combination, acquired resistance frequently involves new mutations in RAS genes or amplification of BRAF itself.²⁴

BRAF Inhibitors in Pediatric Brain Tumors

One of the more encouraging developments is the use of BRAF inhibitors in children with certain brain tumors. BRAF V600E mutations are found in a subset of pediatric gliomas, and these tumors respond remarkably well to targeted therapy. In a study of 56 children with low-grade gliomas, 80% had measurable tumor shrinkage on BRAF inhibition, compared with 28% on conventional chemotherapy. Responses were rapid, appearing within a median of four months, and 86% of responses lasted up to five years while patients continued treatment.²⁵ The catch: when treatment was stopped, about 77% of patients saw their tumors progress rapidly, though rechallenge with the drug produced responses again in 90% of cases.

A randomized trial of dabrafenib plus trametinib in pediatric glioma confirmed these findings, showing an overall response rate of 47% for the combination versus 11% for chemotherapy, and median progression-free survival of about 20 months versus 7 months. The combination also caused far fewer severe side effects than chemotherapy, with grade 3 or higher events in 47% of targeted-therapy patients compared with 94% of those on chemotherapy.²⁶ For families dealing with a child’s brain tumor diagnosis, the combination of better efficacy and fewer harsh side effects represents a meaningful improvement over traditional chemo.

Next-Generation Drugs and the Paradox-Breaker Concept

The limitations of current BRAF inhibitors have driven development of newer drugs designed to overcome paradoxical activation and work against dimeric BRAF forms. Two approaches are in development. One is type II pan-RAF inhibitors, which induce RAF dimer formation but bind both partners in the dimer, effectively shutting down both wild-type RAF dimers and monomeric mutant BRAF. The other is “paradox breakers,” which prevent BRAF from forming dimers altogether by disrupting the structural interface where two BRAF proteins join.²⁷ Both strategies aim to eliminate the paradoxical activation that drives some resistance and some side effects.

Early preclinical work has been promising. Paradox-breaker pan-RAF inhibitors have shown activity not just in solid tumors but also in blood cancers. In testing against acute myeloid leukemia cells, compounds like LY3009120 effectively shut down MAPK signaling and showed synergy with venetoclax, a drug already in use for leukemia.²⁸ If these drugs make it through clinical trials, they could extend the reach of RAF-targeted therapy to mutation classes and cancer types that current BRAF inhibitors can’t touch.

Combining Targeted Therapy with Immunotherapy

The other frontier is combining BRAF/MEK inhibitors with immune checkpoint inhibitors. The rationale is appealing: BRAF inhibitors produce fast, dramatic tumor shrinkage in most patients, while immunotherapy produces slower but potentially longer-lasting responses. In theory, using the targeted drugs to kill off bulk tumor and expose tumor antigens could prime the immune system for a more durable attack. Preclinical studies in mice showed that BRAF and MEK inhibitors could reduce immune-suppressive features of the tumor microenvironment and synergize with checkpoint inhibitors.²⁹ BRAF/MEK inhibitors have been shown to at least transiently improve the immune landscape within tumors, supporting their pairing with immunotherapy.³⁰

Clinical trials of the triple combination have been conducted, with mixed results so far. Toxicity has been a challenge, with some early trial designs causing unacceptable rates of liver inflammation when all three drugs were given together. Sequencing strategies, figuring out whether to start with immunotherapy or targeted therapy, remain an active area of research. For now, most patients receive either targeted therapy or immunotherapy first, with the other class held in reserve for when the first-line treatment stops working.

What Treatment Feels Like for Patients

Beyond survival statistics, quality-of-life data offer a window into the day-to-day experience. In the COLUMBUS trial, patients on the encorafenib-binimetinib combination reported improved quality of life compared with those on vemurafenib alone, with meaningful gains in global health scores and a delay in quality-of-life deterioration.³¹ Dabrafenib similarly showed stable or improved functional dimensions compared with conventional chemotherapy, with patients reporting less pain, less nausea, better appetite, and less fatigue within the first six weeks of treatment. Even patients who crossed over to dabrafenib after progressing on chemotherapy saw improvements across quality-of-life measures.³²

These findings make intuitive sense. BRAF inhibitors are oral pills taken at home, not intravenous infusions requiring hours in a clinic. They tend to produce rapid tumor shrinkage, which relieves cancer-related symptoms quickly. And while they have real side effects, those side effects are generally more manageable on a day-to-day basis than the nausea, hair loss, and immune suppression associated with older chemotherapy regimens. For many patients, the first weeks on a BRAF inhibitor bring a noticeable improvement in how they feel, even as the long-term question of resistance looms.